PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces SensoLyte® HAT (p300) & HAT (pCAF) Assay Kits - AnaSpec is pleased to announce the release of two HAT (histone acetyltransferase) fluorimetric kits adding in our growing list of epigenetics research products
AnaSpec Introduces SensoLyte® HAT (p300) & HAT (pCAF) Assay Kits

 

NewswireToday - /newswire/ - Fremont, CA, United States, 2010/10/14 - AnaSpec is pleased to announce the release of two HAT (histone acetyltransferase) fluorimetric kits adding in our growing list of epigenetics research products.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The SensoLyte p300 Assay Kit provides a convenient assay for the screening of enzyme inhibitors and for continuous measurement of p300 activity. For added convenience, this kit includes two peptide substrates: histone H3 (1-21) peptide and non-histone p53 peptide (368-386). After incubation with acetyl CoA and the substrate, the p300 enzyme generates acetylated H3 or p53 peptide and CoASH. The thiol groups of CoASH can be detected with a fluorogenic reagent at excitation/emission=389nm/513nm.

The SensoLyte HAT (pCAF) Assay Kit provides a convenient assay for screening of enzyme inhibitors and for continuous measurement of pCAF activity. After incubation with acetyl CoA and histone H3 (1-21) peptide, the pCAF enzyme generates acetylated H3 peptide and CoASH. The detection of the CoASH thiol group is the same as above.

Histone acetyltransferases (HATs) enzymes regulate the acetylation of histones and non-histone proteins.1, 2 The acetylation of the -amino groups of lysine residues present at histone tails correlates largely with transcriptional activation, but it is also involved in DNA replication, DNA repair and protein–protein interactions.3 HATs play major roles in the control of cell fate and misregulation is implicated in the development of some human tumors.4,5 HAT p300 is a transcriptional coactivator that acetylates core histones facilitating chromatin decondensation and recruiting basic RNA polymerase machinery.6 Many non-histone proteins, such as p53, STATs, and alpha interferon receptor, also serve as substrates for p300.7 The p300/CBP-associated factor (pCAF) acetylates specific lysines on the N-terminal tails of histones H3 and H4.

References
1. Roth, SY. et al. Annu Rev Biochem. 70, 81 (2001).
2. Glozak, MA. et al. Gene. 363, 15 (2005).
3. Turner, BM. Bioessays 22, 836 (2000).
4. Timmermann, S. et al. Cell Mol Life Sci. 58, 728 (2001).
5. Iyer, NG. et al. Oncogene. 23, 4225 (2004).
6. Chan, HM. et al. J Cell Sci. 114, 2363 (2001).
7. Grossman, SR. Eur J Biochem. 268, 2773 (2001).

About AnaSpec
AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

About Eurogentec
Eurogentec (eurogentec.com) is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces SensoLyte® HAT (p300) & HAT (pCAF) Assay Kits

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)